We observed that lung adenocarcinoma patients with higher levels of the therapy-induced survival signature markers ABCG2, FOS, MAPK13, and NFE2L2 showed a significant higher overall survival of 86, 73, 75.43, and 80 months, respectively (HR = 0.8, p = 0.00017; HR = 0.87, p = 0.023; HR = 0.85, p = 0.0055; HR = 0.84, p = 0.0053), compared to the overall survival of 61, 63.03, 64, and 62 months of patients with low expression levels (Figure 7A, upper panels). This evidence concerns the gene ABCG2 and lung adenocarcinoma.